PolyPid to Present at Israel Controlled Release Society Conference: Insights into PLEX Technology
PorAinvest
miércoles, 3 de septiembre de 2025, 1:22 am ET1 min de lectura
PYPD--
The company's proprietary PLEX technology enables controlled, prolonged drug release, and PolyPid plans to submit a New Drug Application (NDA) for its lead product candidate, D-PLEX₁₀₀, which aims to prevent surgical site infections after colorectal surgeries, expected in early 2026. The company also has a pipeline focused on oncology, obesity, and diabetes [1].
PolyPid's presentation at the ICRS Conference showcases the company's commitment to innovation in drug delivery and its progress in advancing surgical outcomes. The presentation will detail the successful Phase III trial of D-PLEX₁₀₀, highlighting the company's momentum towards potential regulatory approval [1].
However, the submission of the NDA for D-PLEX₁₀₀ is not expected until early 2026, suggesting potential delays in bringing the product to market. Additionally, the focus on a single product candidate for surgical site infections may indicate a lack of diversification in the company's drug development pipeline, making it vulnerable to potential market or regulatory setbacks [1].
References:
[1] https://www.quiverquant.com/news/PolyPid+Ltd.+to+Present+at+Israel+Controlled+Release+Society+Conference+on+Advances+in+Drug+Delivery+Technology
PolyPid Ltd. (PYPD) will present at the 14th Israel Controlled Release Society Conference. Deputy CEO Dalit Hazan will present "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial." The company specializes in advanced drug delivery systems to improve surgical outcomes. PolyPid plans to submit an NDA for its lead product candidate, D-PLEX, by early 2026.
PolyPid Ltd. (PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, has announced that Deputy CEO Dalit Hazan will present at the 14th Israel Controlled Release Society (ICRS) Conference. The presentation, titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial," will take place on September 7, 2025, from 5:25 PM to 5:45 PM local time as part of a session on advances in targeted drug delivery [1].The company's proprietary PLEX technology enables controlled, prolonged drug release, and PolyPid plans to submit a New Drug Application (NDA) for its lead product candidate, D-PLEX₁₀₀, which aims to prevent surgical site infections after colorectal surgeries, expected in early 2026. The company also has a pipeline focused on oncology, obesity, and diabetes [1].
PolyPid's presentation at the ICRS Conference showcases the company's commitment to innovation in drug delivery and its progress in advancing surgical outcomes. The presentation will detail the successful Phase III trial of D-PLEX₁₀₀, highlighting the company's momentum towards potential regulatory approval [1].
However, the submission of the NDA for D-PLEX₁₀₀ is not expected until early 2026, suggesting potential delays in bringing the product to market. Additionally, the focus on a single product candidate for surgical site infections may indicate a lack of diversification in the company's drug development pipeline, making it vulnerable to potential market or regulatory setbacks [1].
References:
[1] https://www.quiverquant.com/news/PolyPid+Ltd.+to+Present+at+Israel+Controlled+Release+Society+Conference+on+Advances+in+Drug+Delivery+Technology
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios